AU2016333903B2 - Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof - Google Patents

Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof Download PDF

Info

Publication number
AU2016333903B2
AU2016333903B2 AU2016333903A AU2016333903A AU2016333903B2 AU 2016333903 B2 AU2016333903 B2 AU 2016333903B2 AU 2016333903 A AU2016333903 A AU 2016333903A AU 2016333903 A AU2016333903 A AU 2016333903A AU 2016333903 B2 AU2016333903 B2 AU 2016333903B2
Authority
AU
Australia
Prior art keywords
ser
thr
gly
leu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016333903A
Other languages
English (en)
Other versions
AU2016333903A1 (en
Inventor
Jeanne Allinne
Yu Bai
Wen Fury
Jamie M. Orengo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2016333903A1 publication Critical patent/AU2016333903A1/en
Application granted granted Critical
Publication of AU2016333903B2 publication Critical patent/AU2016333903B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57527—Calcitonin gene related peptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/585—Calcitonins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
AU2016333903A 2015-10-06 2016-10-05 Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof Active AU2016333903B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562237624P 2015-10-06 2015-10-06
US62/237,624 2015-10-06
PCT/US2016/055502 WO2017062456A2 (en) 2015-10-06 2016-10-05 Biomarkers related to interleukin-33 (il-33)-mediated diseases and uses thereof

Publications (2)

Publication Number Publication Date
AU2016333903A1 AU2016333903A1 (en) 2018-04-26
AU2016333903B2 true AU2016333903B2 (en) 2021-07-08

Family

ID=57223756

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016333903A Active AU2016333903B2 (en) 2015-10-06 2016-10-05 Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof

Country Status (12)

Country Link
US (2) US10005834B2 (cg-RX-API-DMAC7.html)
EP (1) EP3359567A2 (cg-RX-API-DMAC7.html)
JP (1) JP6858182B2 (cg-RX-API-DMAC7.html)
KR (1) KR102687412B1 (cg-RX-API-DMAC7.html)
CN (1) CN108137682A (cg-RX-API-DMAC7.html)
AU (1) AU2016333903B2 (cg-RX-API-DMAC7.html)
CA (1) CA3000725A1 (cg-RX-API-DMAC7.html)
EA (1) EA201890891A1 (cg-RX-API-DMAC7.html)
HK (2) HK1259386A1 (cg-RX-API-DMAC7.html)
MA (1) MA50638A (cg-RX-API-DMAC7.html)
MX (1) MX2018004170A (cg-RX-API-DMAC7.html)
WO (1) WO2017062456A2 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102400060B1 (ko) 2013-12-26 2022-05-19 미쓰비시 타나베 파마 코퍼레이션 인간 항 il-33 중화 단일클론 항체
SG10201805934RA (en) 2014-01-10 2018-08-30 Anaptysbio Inc Antibodies directed against interleukin-33 (il-33)
US20160168640A1 (en) 2014-11-10 2016-06-16 Genentech, Inc. Therapeutic and diagnostic methods for il-33-mediated disorders
KR20170080604A (ko) 2014-11-10 2017-07-10 제넨테크, 인크. 항-인터류킨-33 항체 및 그것의 용도
KR102687412B1 (ko) 2015-10-06 2024-07-24 리제너론 파아마슈티컬스, 인크. 인터루킨-33(il-33)-매개된 질환과 관련된 바이오마커 및 이의 용도
EA037960B1 (ru) 2016-04-27 2021-06-15 Эббви Инк. Способ лечения эозинофильного эзофагита с применением антитела против il-13
SG11201808693WA (en) 2016-04-27 2018-11-29 Pfizer Anti-il-33 antibodies, compositions, methods and uses thereof
CN110431240A (zh) 2017-04-13 2019-11-08 雷杰纳荣制药公司 在编码il33和il1rl1的基因中具有风险等位基因的患者的炎症性肺部疾病的治疗和抑制
JP7657440B2 (ja) 2017-06-12 2025-04-07 ブルーフィン バイオメディシン， インコーポレイテッド 抗－ｉｌ１ｒａｐ抗体および抗体薬物コンジュゲート
CN115920041A (zh) * 2017-08-31 2023-04-07 田边三菱制药株式会社 含有il-33拮抗剂的子宫内膜异位症治疗剂
CN109061139A (zh) * 2018-06-19 2018-12-21 温州医科大学附属第医院 血清炎性生物标志物在防治急性缺血性脑梗死中的应用
TW202519263A (zh) * 2019-03-21 2025-05-16 美商再生元醫藥公司 含有抗il-33抗體之穩定調配物
EP4114414A4 (en) * 2020-03-06 2024-03-27 The Regents of The University of Michigan Serine protease inhibitors for suppressing or preventing anaphylactic reaction
KR20220152262A (ko) 2020-03-13 2022-11-15 제넨테크, 인크. 항-인터루킨-33 항체 및 이의 용도
JP7578943B2 (ja) * 2020-07-13 2024-11-07 学校法人自治医科大学 褥瘡治療剤
CN114814242B (zh) * 2022-06-10 2025-04-01 中日友好医院(中日友好临床医学研究所) 一种诊断慢性阻塞性肺疾病患者肌肉减少症的血液学标志物
EP4658247A1 (en) * 2023-01-31 2025-12-10 Vivacelle Bio, Inc. Compositions and methods for treating hyperprocalcitonemia
KR102834740B1 (ko) * 2023-04-10 2025-07-17 아주대학교산학협력단 Hsp10 또는 이의 항체를 유효성분으로 포함하는 만성 자발적 두드러기의 진단을 위한 바이오마커 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110189698A1 (en) * 2008-08-28 2011-08-04 The Regents Of The University Of California Protein Biomarkers and Methods for Diagnosing Kawasaki Disease
US20140271658A1 (en) * 2013-03-13 2014-09-18 Regeneron Pharmaceuticals, Inc. Anti-il-33 antibodies and uses thereof
US20140271642A1 (en) * 2013-03-15 2014-09-18 Regeneron Pharmaceuticals, Inc. Il-33 antagonists and uses thereof
WO2015061441A1 (en) * 2013-10-23 2015-04-30 Genentech, Inc. Methods of diagnosing and treating eosinophilic disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4227454C1 (de) * 1992-08-19 1994-02-03 Henning Berlin Gmbh Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens
NZ549040A (en) * 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
KR102687412B1 (ko) 2015-10-06 2024-07-24 리제너론 파아마슈티컬스, 인크. 인터루킨-33(il-33)-매개된 질환과 관련된 바이오마커 및 이의 용도

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110189698A1 (en) * 2008-08-28 2011-08-04 The Regents Of The University Of California Protein Biomarkers and Methods for Diagnosing Kawasaki Disease
US20140271658A1 (en) * 2013-03-13 2014-09-18 Regeneron Pharmaceuticals, Inc. Anti-il-33 antibodies and uses thereof
US20140271642A1 (en) * 2013-03-15 2014-09-18 Regeneron Pharmaceuticals, Inc. Il-33 antagonists and uses thereof
WO2015061441A1 (en) * 2013-10-23 2015-04-30 Genentech, Inc. Methods of diagnosing and treating eosinophilic disorders

Also Published As

Publication number Publication date
WO2017062456A3 (en) 2017-05-18
EA201890891A1 (ru) 2018-09-28
EP3359567A2 (en) 2018-08-15
KR20180053682A (ko) 2018-05-23
US10005834B2 (en) 2018-06-26
US20170096483A1 (en) 2017-04-06
AU2016333903A1 (en) 2018-04-26
HK1259386A1 (zh) 2019-11-29
CA3000725A1 (en) 2017-04-13
WO2017062456A2 (en) 2017-04-13
US10851158B2 (en) 2020-12-01
JP2018533557A (ja) 2018-11-15
MA50638A (fr) 2020-08-05
JP6858182B2 (ja) 2021-04-14
KR102687412B1 (ko) 2024-07-24
MX2018004170A (es) 2018-06-06
CN108137682A (zh) 2018-06-08
US20180258164A1 (en) 2018-09-13
HK1255972A1 (zh) 2019-09-06

Similar Documents

Publication Publication Date Title
AU2016333903B2 (en) Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof
KR102780485B1 (ko) 염증 질환의 치료 방법
AU2020277207B2 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
KR102103159B1 (ko) 항-ｉｌ-33 항체 및 이의 용도
DK2475684T3 (en) HUMAN HIGH-EFFICIENCY ANTIBODIES AGAINST HUMAN PROTEASE-ACTIVATED RECEPTOR-2
ES2675917T3 (es) Uso médico de anticuerpos humanos de alta afinidad dirigidos contra el receptor humano de IL-4
AU2013243644B2 (en) Anti-HLA-B*27 antibodies and uses thereof
KR102563568B1 (ko) 렙틴 수용체에 길항하는 항원-결합 단백질
KR20140014067A (ko) 항-cd48 항체 및 그의 용도
KR20180070609A (ko) 렙틴 수용체를 활성화하는 항원-결합 단백질
AU2019329958B2 (en) Methods and compositions for treating subjects having rheumatoid arthritis
WO2015116852A1 (en) Methods for treating rheumatoid arthritis by administering an il-6r antibody
EA040089B1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)